Drug discovery and development is advancing by leaps and bounds as genetic medicines progress under a growing number of biotech companies. In the view

AI-driven Deep Genomics gets $180M to turn biology into informational medicines - MedCity News

submited by

Style Pass

2021-07-29 14:30:10

Drug discovery and development is advancing by leaps and bounds as genetic medicines progress under a growing number of biotech companies. In the view of Brendan Frey, founder and CEO of startup Deep Genomics, while the drugs of the 20th century revolved around small molecule chemistry, drugs of the 21st century will be based on information: the sequence of letters in genetic code that determine health and disease.

Deep Genomics uses artificial intelligence to analyze genetic data. The technology of the Toronto-based company is feeding a pipeline of drug candidates, internal and partnered, that are advancing to clinical testing. Frey is now floating the ambitious goal of making Deep Genomics the world’s leader in producing and selling genetic medicines.

“Medicines are information now,” Frey said. “How do we convert the complex biology to a way to design new medicines? To dominate this entire area, we need a way to convert this complex biology to this informational medicine.”